Date of Award
Master of Science (MS)
Debra M. Moriarity
Luis R. Cruz-Vera
John W. Shriver
William N. Setzer
DNA topoisomerases., Caffeine--Physiological effect., Pharmacognosy., Antineoplastic agents.
The essential nature of topoisomerase II makes it an ideal target for anticancer drugs. Such anticancer agents may either interfere with the catalytic activity of the enzyme, or cause it to induce permanent double-stranded breaks in the DNA. In this study, ten anticancer agents (berberine, chelerythrine, doxorubicin, sanguinarine, tingenone, paclitaxel, malvidin, delphinidin, ellipticine, and pelargonidin) were studied through gel electrophoresis assays to determine their ability to inhibit topoisomerase II activity. Caffeine has been shown to reduce the effectiveness of some topoisomerase II-targeting anticancer drugs. This ability was evaluated by the addition of caffeine in concentrations ranging from 165 nM to 50 mM. Caffeine was found to affect the intercalative ability of doxorubicin, sanguinarine, delphinidin, and ellipticine. Caffeine was also found to potentiate the effects of tingenone, delphinidin, and ellipticine, as well as the combination of berberine and delphinidin. When tested in combination, interactions between several drug pairs were observed.
Knott, Erika, "Caffeine modulation of anticancer drug activity against topoisomerase II" (2014). Theses. 60.